In addition, we found that SF-DFO, a compound that mimics hypoxia and targets bone tissue, can partially alleviate symptoms of STZ-induced T1DM by activating the HIF-1α-RegIIIγ pathway in the skeleton. This evidence concerns the gene HIF1A and type 1 diabetes mellitus.